Tue Sep 17 06:15:00 UTC 2024: ## Sernova Corp. (TSE:SVA) Sees Upgraded Earnings Forecast, Insider Trading Activity

**Toronto, Canada – September 17, 2024** – Sernova Corp. (TSE:SVA), a Canadian clinical-stage regenerative medicine company, has received an upgraded earnings forecast for FY2027 from Leede Financial. Analyst D. Loe now anticipates the company to earn ($0.02) per share for the year, an improvement from the previous estimate of ($0.03). Leede Financial maintains a “Speculative Buy” rating and a $1.50 target price on Sernova stock.

This positive outlook comes after Sernova reported C($0.03) earnings per share for the quarter ending June 14th, meeting analyst expectations. The company is currently developing and commercializing regenerative medicine therapeutics, notably its Cell Pouch technology.

Sernova’s stock opened at C$0.25 on Monday, with a 50-day moving average of C$0.27 and a 200-day moving average of C$0.37. The stock has traded between C$0.20 and C$0.83 in the past year. The company boasts a market cap of C$79.48 million and a PE ratio of -1.88.

In recent insider transactions, Director Steven Sangha sold 930,000 shares on August 27th at an average price of C$0.24, for a total value of C$223,200.00. Meanwhile, other insiders purchased 359,600 shares worth $92,771 in the last quarter, highlighting their continued confidence in the company. Corporate insiders collectively hold 12.98% of Sernova’s stock.

**For investors looking for updates on Sernova, MarketBeat.com provides a free daily email newsletter summarizing news and analyst ratings.**

Read More